Currently, there is no direct evidence for the contribution of IL-17F to the progression of IPF; however, these observations related to IL-17A and inflammatory responses suggest that IL-17F may be an effective target for the treatment of IPF. The gene discussed is IL17F; the disease is idiopathic pulmonary fibrosis.